We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.
Shield Therapeutics is a well-funded, high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.
Through development and commercialisation of lead assets such as Accrufer® / Feraccru® and PT20, Shield continues to build an integrated and ultimately profitable speciality pharmaceutical business.
Shield is well positioned to become a fast growing, independent, international specialty pharmaceutical company due to the strength of its products and team, and with great thanks to all of our supportive shareholders.
5 Jan 2022
Shield Therapeutics plc announces that it has entered into an exclusive licence agreement for Accrufer® with KYE Pharmaceuticals Inc. in Canada. For further details click here.